FTX-2

FTX-2 is an experimental small-molecule calmodulin pathway modulator that has been studied preclinically for its ability to reduce aberrant p53 activity in hematopoietic stem and progenitor cells, with potential application in sickle cell disease and related hemoglobinopathies. In comparative in vitro work, FTX-2 and its analog FTX-1 demonstrated superior activity to the reference calmodulin inhibitor trifluoperazine in normalizing dysfunctional p53 signaling in CD34-positive human hematopoietic stem and progenitor cells, suggesting a differentiated pharmacological profile and possibly improved therapeutic index over older calmodulin-directed agents.[11] Detailed structure, pharmacokinetics, and clinical development status have not been publicly disclosed, and FTX-2 remains at the preclinical, discovery-stage level based on currently available information.